JPWO2021212123A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021212123A5 JPWO2021212123A5 JP2022562788A JP2022562788A JPWO2021212123A5 JP WO2021212123 A5 JPWO2021212123 A5 JP WO2021212123A5 JP 2022562788 A JP2022562788 A JP 2022562788A JP 2022562788 A JP2022562788 A JP 2022562788A JP WO2021212123 A5 JPWO2021212123 A5 JP WO2021212123A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- fusion protein
- nucleic acid
- vector
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000037865 fusion proteins Human genes 0.000 claims description 53
- 108020001507 fusion proteins Proteins 0.000 claims description 53
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 44
- 229920001184 polypeptide Polymers 0.000 claims description 42
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 42
- 150000007523 nucleic acids Chemical class 0.000 claims description 31
- 108020004707 nucleic acids Proteins 0.000 claims description 30
- 102000039446 nucleic acids Human genes 0.000 claims description 30
- 230000002163 immunogen Effects 0.000 claims description 26
- 239000013598 vector Substances 0.000 claims description 26
- 230000000890 antigenic effect Effects 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 24
- 239000012634 fragment Substances 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 13
- 230000028993 immune response Effects 0.000 claims description 9
- 230000003308 immunostimulating effect Effects 0.000 claims description 8
- 210000004027 cell Anatomy 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 239000003446 ligand Substances 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 229960005486 vaccine Drugs 0.000 claims description 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 208000030381 cutaneous melanoma Diseases 0.000 claims description 4
- 201000003708 skin melanoma Diseases 0.000 claims description 4
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims description 2
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims description 2
- 102000014150 Interferons Human genes 0.000 claims description 2
- 108010050904 Interferons Proteins 0.000 claims description 2
- 102000000440 Melanoma-associated antigen Human genes 0.000 claims description 2
- 108050008953 Melanoma-associated antigen Proteins 0.000 claims description 2
- 108091034117 Oligonucleotide Proteins 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 230000005867 T cell response Effects 0.000 claims description 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims description 2
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims description 2
- 201000005969 Uveal melanoma Diseases 0.000 claims description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical group [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims description 2
- -1 aminoalkyl glucosaminide Chemical class 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000002158 endotoxin Substances 0.000 claims description 2
- 229960001438 immunostimulant agent Drugs 0.000 claims description 2
- 239000003022 immunostimulating agent Substances 0.000 claims description 2
- 229940047124 interferons Drugs 0.000 claims description 2
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 229930182490 saponin Natural products 0.000 claims description 2
- 150000007949 saponins Chemical class 0.000 claims description 2
- 235000017709 saponins Nutrition 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims 8
- 239000000126 substance Substances 0.000 claims 1
- 239000013603 viral vector Substances 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241000710929 Alphavirus Species 0.000 description 1
- 241000712891 Arenavirus Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20170174.5 | 2020-04-17 | ||
| EP20170174 | 2020-04-17 | ||
| PCT/US2021/028029 WO2021212123A1 (en) | 2020-04-17 | 2021-04-19 | Fusion proteins of ctl antigens for treating melanoma |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023522198A JP2023522198A (ja) | 2023-05-29 |
| JP2023522198A5 JP2023522198A5 (https=) | 2024-05-20 |
| JPWO2021212123A5 true JPWO2021212123A5 (https=) | 2024-05-20 |
Family
ID=70295067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022562788A Pending JP2023522198A (ja) | 2020-04-17 | 2021-04-19 | 黒色腫を治療するためのｃｔｌ抗原の融合タンパク質 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230167163A1 (https=) |
| EP (1) | EP4136097A1 (https=) |
| JP (1) | JP2023522198A (https=) |
| CN (1) | CN116057067A (https=) |
| CA (1) | CA3179694A1 (https=) |
| WO (1) | WO2021212123A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021005338A2 (en) * | 2019-07-05 | 2021-01-14 | The Francis Crick Institute Limited | Novel cancer antigens and methods |
| JP2023522193A (ja) * | 2020-04-17 | 2023-05-29 | ザ フランシス クリック インスティチュート リミティッド | 抗原プール |
| WO2025202937A1 (en) | 2024-03-26 | 2025-10-02 | BioNTech SE | Cancer vaccines |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1053325E (pt) * | 1998-02-05 | 2006-05-31 | Glaxosmithkline Biolog Sa | Derivados de antigenios associados a tumores da familia mage e, sequencias de acidos nucleicos que os codificam, utilizados para a preparacao de proteinas de fusao e de composicoes para vacinacao. |
| CN100419079C (zh) * | 1998-07-14 | 2008-09-17 | 科里克萨有限公司 | 用于治疗和诊断前列腺癌的组合物和方法 |
| US6770456B1 (en) | 1998-07-29 | 2004-08-03 | Ludwig Institute For Cancer Research | Endogenous retrovirus tumor associated nucleic acids and antigens |
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| EP1586330A1 (en) * | 2004-04-16 | 2005-10-19 | Georg-August-Universität Göttingen | Vaccination against malignant melanoma |
| DK1871391T3 (da) | 2005-03-30 | 2012-04-16 | Viroxis | Endogen retrovirus og proteiner, der kodes af env som target for cancerbehandling |
| AT502292B1 (de) | 2005-05-11 | 2010-04-15 | Avir Green Hills Biotechnology | Melanomdiagnose |
| US8921050B2 (en) | 2006-03-17 | 2014-12-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of diagnosing renal cell carcinoma |
| US20080019979A1 (en) | 2006-05-22 | 2008-01-24 | Feng Wang-Johanning | HERV-K Antigens, Antibodies, and Methods |
| CN101638440B (zh) * | 2008-07-29 | 2011-10-26 | 中国人民解放军军事医学科学院基础医学研究所 | 一种可诱发机体抗肿瘤免疫的异种抗原-Fc融合蛋白及其应用 |
| BR112021006941A2 (pt) * | 2018-10-19 | 2021-08-31 | The Francis Crick Institute Limited | Antígenos de câncer inovadores e métodos |
| AU2020302285A1 (en) * | 2019-06-28 | 2021-12-02 | Enara Bio Limited | Novel cancer antigens and methods |
| WO2021005338A2 (en) * | 2019-07-05 | 2021-01-14 | The Francis Crick Institute Limited | Novel cancer antigens and methods |
-
2021
- 2021-04-19 CN CN202180043464.9A patent/CN116057067A/zh active Pending
- 2021-04-19 CA CA3179694A patent/CA3179694A1/en active Pending
- 2021-04-19 JP JP2022562788A patent/JP2023522198A/ja active Pending
- 2021-04-19 WO PCT/US2021/028029 patent/WO2021212123A1/en not_active Ceased
- 2021-04-19 EP EP21723936.7A patent/EP4136097A1/en active Pending
-
2022
- 2022-10-14 US US18/046,675 patent/US20230167163A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017297610B2 (en) | Compositions and methods for alphavirus vaccination | |
| ES2117052T5 (es) | Induccion de respuestas de linfocitos t citotoxicos. | |
| EA003832B1 (ru) | Ген-доставочный комплекс для чрескожной доставки чужеродного генетического материала в антиген-презентирующие клетки и способы его использования | |
| US20040033585A1 (en) | Flexible vaccine assembly and vaccine delivery platform | |
| CN103002909A (zh) | 包含含有至少一个cxxc基序的多肽和异源抗原的药物组合物及其用途 | |
| Qazi et al. | Enhancement of DNA vaccine potency by linkage of Plasmodium falciparum malarial antigen gene fused with a fragment of HSP70 gene | |
| TW200902049A (en) | Fusion protein | |
| US20200246443A1 (en) | Therapeutic cancer vaccine targeted to haah (aspartyl-[asparaginyl]-beta-hydroxylase) | |
| JP2022046617A (ja) | 異種ポリペプチドを含むＣｙａＡベースのキメラタンパク質及び免疫応答の誘導におけるその使用 | |
| KR20200027499A (ko) | 암 치료용 신생항원 백신 조성물 | |
| CN115820696A (zh) | 治疗性多价HPV mRNA疫苗及其制备方法 | |
| WO2023051701A1 (zh) | 抗SARS-CoV-2感染的mRNA、蛋白以及抗SARS-CoV-2感染的疫苗 | |
| KR20230084478A (ko) | 면역원성 코로나 바이러스 융합 단백질 및 관련 방법 | |
| JPWO2021163438A5 (https=) | ||
| CN115944722A (zh) | 一种抗肿瘤mRNA疫苗及其制备方法和应用 | |
| JPWO2021212123A5 (https=) | ||
| CN117883563B (zh) | 一种mRNA疫苗及其制备方法与应用 | |
| CN119770633A (zh) | 一种改进型多肽肿瘤疫苗组成与应用 | |
| CN114650838A (zh) | 肿瘤特异性多肽序列及其应用 | |
| JP2008500802A5 (https=) | ||
| RU2781294C1 (ru) | Конъюгат белка рецепторсвязывающего домена (RBD) поверхностного гликопротеина S вируса SARS-CoV-2 с полимером полиглюкин-спермидин (PGS) и вакцинный комплекс против коронавирусной инфекции COVID-19 на основе указанного конъюгата и плазмидной ДНК pVAX-RBD | |
| JPWO2020079448A5 (https=) | ||
| JPWO2019142933A1 (ja) | 選択的ｃｄ８陽性ｔ細胞誘導ワクチン抗原 | |
| JPWO2020260897A5 (https=) | ||
| US8921534B2 (en) | Enhancement of the immune response using CD36-binding domain |